Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) (SYNPHENY-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05764239

Recruitment Status : Terminated (Based on a review of early data from participants in the dose escalation phase, it was determined that SYNB1934v1 is unlikely to meet the study's primary endpoint for lowering phenylalanine (Phe) levels in patients.)

First Posted : March 10, 2023

Last Update Posted : March 21, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Synlogic

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	February 8, 2024
Actual Study Completion Date :	March 15, 2024

To Top